SCHEMBL6498904

SCHEMBL6498904

COc1cccc(-c2ccc(C(=O)NC3CC4CNC3C4)s2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.50
HSD17B2 P37059 11/20 0.47
HSD17B1 P14061 9/20 0.47
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
MAP4K4 O95819 1/20 0.43
PRKACA P17612 1/20 0.43
GRK5 P34947 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CDK8 P49336 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491196 0.90 KDM4E (0.55) HSD17B2HSD17B1KDM4ESMN1; SMN2NPC1
SCHEMBL6487853 0.87 RXFP1 (0.47) HSD17B2HSD17B1KDM4ESMN1; SMN2NPC1
SCHEMBL6497432 0.86 CHRNA7 (0.54) KDM4ESMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL6485890 0.86 HPGDS (0.49) HSD17B2HSD17B1CHRNA7HTR3EHTR3B
SCHEMBL6501584 0.85 HPGDS (0.50) HSD17B2HSD17B1KDM4ENPC1ALDH1A1
SCHEMBL6490039 0.85 MAPK11 (0.47) HSD17B2HSD17B1KDM4ENPC1ALDH1A1
SCHEMBL6487135 0.85 ESRRG (0.50) MAPTCHRNA7HTR3EHTR3BHTR3A
SCHEMBL6487221 0.85 HDAC6 (0.49) HDAC6HSD17B2HSD17B1KDM4ESMN1; SMN2
SCHEMBL6495173 0.83 NQO2 (0.51) HSD17B2HSD17B1SMN1; SMN2NPC1MAPT
SCHEMBL6500579 0.83 HDAC6 (0.51) HDAC6HSD17B2HSD17B1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 HDAC6 1069/4885HSD17B2 517/4885HSD17B1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.